The company's lead program, KIACTA™, is a drug candidate for the treatment of AA amyloidosis, a rare disease that affects the kidneys and often leads to dialysis and death. BELLUS Health is partnered with Auven Therapeutics for the development of KIACTA™. They are also developing KIACTA™ as a treatment for sarcoidosis, a potentially fatal inflammatory lung condition. Another drug in their pipeline is Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by E. coli. They are conducting pre-clinical studies for Shigamab™. BELLUS Health is also working on a research-stage project for the treatment of AL amyloidosis. Additionally, the company is developing BLU-5937, a P2X3 antagonist for chronic cough and other hypersensitization-related disorders. BELLUS Health is based in Laval, Quebec, and its shares trade on the Toronto Stock Exchange and Nasdaq.